UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
Location status: Recruiting
NCT Number: NCT06618274
This health services interventional study investigates the effectiveness of central oncology navigation (SOC ) alone and central oncology navigation with a new role called an "oncology research navigator (ORN)" who is embedded in central oncology navigation cancer care delivery. This study will examine two patient cohorts: Cohort 1 will enroll patients with new cancer appointments within genitourinary (GU) or thoracic cancers. These clinics have not yet implemented the central navigation program. Participants will be enrolled pre- and post-implementation of the central oncology navigator within these cancer groups to evaluate the effectiveness of the central oncology navigator alone. The second cohort will enroll participants with new cancer appointments within gastrointestinal (GI), hematology, and breast cancer (clinics where the central navigation program was implemented). These individuals will be randomized to receive standard of care, which for these cancer types includes central oncology navigation or the intervention of an oncology research navigator in addition to SOC. This intervention will involve baseline and biweekly follow-up for a total of 3 months. Interactions with the ORN will include facilitating participation in supportive care services and clinical trials. All participants will undergo baseline and follow-up patient-reported outcomes and data collection. The study will evaluate the impact of the central oncology navigation program alone, as well as the addition of the ORN on patient quality of life, as well as enrollment into studies and participation in supportive care services. Additional analyses will evaluate the impact of the central oncology navigation program on patient experience, patient activation, net promoter scores, and overall survival.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Chapel Hill, North Carolina, 27599, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
In order to participate in this study a subject must meet all of the eligibility criteria outlined below.
Exclusion criteria
The intervention of oncology research navigator or Oncology research navigator (ORN) is embedded in central oncology navigation cancer care delivery.
Other names: oncology research navigator (ORN
Central oncology navigation (SOC ) alone.
Time frame: Up to 6 months
Participation in at least 1 supportive service offered will be measured by the number of patients receiving services. This information will be gathered from chart review.
Time frame: Up to 6 months
Enrollment into non-treatment clinical studies will be measured by the number of patients enrolled at any time. This information will be gathered from chart review.
Time frame: Baseline and 3 months
Cohort 1: Health-related quality of life will be measured using the PROMIS Global Health. The PROMIS Global Health is a comprehensive tool designed to assess an individual's overall physical, mental, and social health and includes 10 items that cover various health domains. These items are divided into two main components: Global Physical Health and Global Mental Health. Global Physical Health: This includes items related to physical functioning, pain, fatigue, and overall physical health. Global Mental Health: This includes items related to mental health, emotional distress, and social health.Response Options: Each item is rated on a 5-point Likert scale, with higher scores indicating better health.Raw Scores: The responses are summed to create raw scores for both the Global Physical Health and Global Mental Health components.
Time frame: Baseline and 3 months
Cohort 1: Patient activation will be measured using Patient Activation Measure -13 (PAM-13). PAM-13 is a validated questionnaire designed to assess an individual's knowledge, skills, and confidence in managing their own health and healthcare. It consists of 13 items that measure patient activation, which is the extent to which individuals feel capable of managing their health. The PAM 13 includes 13 statements that respondents rate based on their level of agreement, ranging from "Strongly Disagree" to "Strongly Agree." Responses are scored on a scale from 0 to 100. Higher scores indicate greater patient activation.
Time frame: Baseline and 3 months
Cohort 1: Patient experience will be measured using the Consumer Assessment of Healthcare Providers and Systems (CAHPs) cancer care survey. Scoring will be any number from 0 to 10, where 0 is the worst cancer care team possible and 10 is the best cancer care team possible, what number would you use to rate your cancer care team? (0-10 rating, from "worst cancer care team possible" to "best cancer care team possible" 2. Considering all your cancer care at this cancer center, using any number from 0 to 10, where 0 is the worst overall cancer care experience possible and 10 is the best overall cancer care experience possible, what number would you use to rate your overall cancer care experience? (0-10 rating, from "worst overall cancer care experience possible" to "best overall cancer care experience possible")
Time frame: Baseline and 3 months
Cohort 1: Net promoter scores will be measured using the net promoter score survey.
The Net Promoter Score (NPS) is used as a metric for assessing customer loyalty and satisfaction. NPS measures the likelihood of customers to recommend a company's product or service to others. It is based on a single question: "On a scale from 0 to 10, how likely are you to recommend our product/service to a friend or colleague?"
Time frame: Up to 5 years
Cohort 1: Overall Survival, defined as death by any cause from the time of enrollment will be measured. Any patient who has not died by the analysis date will be censored. Sub-analyses for cancer types will be conducted.
Time frame: Baseline and 3 months
Cohort 2: Health-related quality of life will be measured using the PROMIS Global Health 10-item instrument in all participants The PROMIS Global Health is a comprehensive tool designed to assess an individual's overall physical, mental, and social health and includes 10 items that cover various health domains. These items are divided into two main components: Global Physical Health and Global Mental Health. Global Physical Health: This includes items related to physical functioning, pain, fatigue, and overall physical health. Global Mental Health: This includes items related to mental health, emotional distress, and social health.Response Options: Each item is rated on a 5-point Likert scale, with higher scores indicating better health.Raw Scores: The responses are summed to create raw scores for both the Global Physical Health and Global Mental Health components.
Contact information is provided by the study sponsor or research team.
Allison Ross
CONTACT
Mireille Leone
CONTACT
UNC Lineberger Comprehensive Cancer Center
Other
Navigation and Research: Evaluating the Intervention of Central Navigation and an Oncology Research Navigator (ORN) on Cancer Outcomes and Clinical Trial Enrollment (NAVIGATE Trial)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06674889
Cancer, Malignant Tumor
Chapel Hill, North Carolina, United States
View Trial DetailsNCT04952766
Acquired Immunodeficiency Syndrome, Autoimmune Diseases
Orléans, France
View Trial DetailsNCT05754801
Cancer, Neoplasms
Hong Kong
View Trial DetailsNCT05885048
Cancer, Effects of Immunotherapy
Bern, Switzerland
View Trial Details